Adicet Bio, Inc. (ACET)

Market Cap	115.04M
Revenue (ttm)	n/a
Net Income (ttm)	-139.79M
Shares Out	82.17M
EPS (ttm)	-2.94
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,663,004
Open	1.410
Previous Close	1.330
Day's Range	1.380 - 1.530
52-Week Range	1.100 - 6.885
Beta	1.76
Analysts	Buy
Price Target	13.86 (+890.0%)
Earnings Date	May 14, 2024

About ACET

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Th...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1947
• Employees: 143
• Stock Exchange: NASDAQ
• Ticker Symbol: ACET

Analyst Forecast

According to 8 analysts, the average rating for ACET stock is "Buy." The 12-month stock price forecast is $13.86, which is an increase of 890.00% from the latest price.

Price Target

$13.86

(890.00% upside)

Analyst Consensus: Buy